Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
tyrosine kinase inhibitor
Biotech
Exelixis’ Cabometyx successor misses primary endpoint in CRC trial
While the zanzalintinib study is still technically positive, it could draw FDA scrutiny because Exelixis changed its primary endpoint twice.
Angus Liu
Jun 22, 2026 3:40pm
At ASCO 2026, a ‘paradigm shift’ for a rare gut cancer looms
Jun 1, 2026 3:55pm
Nuvalent races to FDA to challenge Pfizer for lung cancer market
Nov 17, 2025 7:45am
Cogent eyes FDA approval after clearing another ph. 3 hurdle
Nov 10, 2025 10:57am
JPM25: M&A strategist GSK acquires IDRx for $1B upfront
Jan 13, 2025 2:00am
Alumis raises $259M in 2024's largest biotech round so far
Mar 6, 2024 8:00am
